Genetic and Non-genetic Factors Contributing to the Significant Variation in the Plasma Trough Concentration-to-Dose Ratio of Valproic Acid in Children With Epilepsy.

This study was conducted to evaluate the potential genetic and non-genetic factors contributing to plasma trough concentration-to-dose ( /) ratio of valproic acid (VPA) in pediatric patients with epilepsy. A single-center, retrospective cohort study was performed by collecting data from 194 children aged 1-14 years between May 2018 and November 2018. The oral solution ( = 135) group and the sustained-release (SR) tablet group ( = 59) were defined, and the plasma VPA was measured. Twenty-six single-nucleotide polymorphisms (SNPs) were chosen for genotyping with the MassARRAY system. A multiple logistic regression model was used for data analysis. Body weight (BW) and age were positively correlated with the / ratio in 194 patients, but the positive correlation disappeared after the patients were divided into oral solution and SR tablet subgroups. The average / ratio was significantly increased by 2.11-fold ( = 0.000) in children who took VPA SR tablets compared with children who were administered VPA oral solutions. No significant association between genetic variants and the / ratio was found, even for the five well-studied SNPs, namely G211T, C802T, C161T, T125C, and A1075C. However, a significant association between the / ratio and Del>A (rs144486213) was observed in the VPA oral solution group, but not in the VPA SR tablet group. The dosage forms of sodium valproate, rather than BW, age, or genetic polymorphisms, significantly affected the VPA / ratios in pediatric patients with epilepsy. Based on our findings, switching the dosage form between solution and SR tablet should be performed cautiously. Total daily dose adjustment should be considered, and the plasma concentration, seizure-control effect, and adverse drug reaction should also be monitored very closely.